**Core Concept**
Imatinib is a tyrosine kinase inhibitor (TKI) that targets specific enzymes involved in the proliferation and survival of cancer cells. It works by selectively inhibiting the BCR-ABL tyrosine kinase, which is a result of the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).

**Why the Correct Answer is Right**
Imatinib binds to the ATP-binding site of the BCR-ABL tyrosine kinase, preventing the enzyme from phosphorylating downstream signaling molecules that promote cell proliferation and survival. This leads to apoptosis (programmed cell death) of cancer cells and a reduction in tumor size. Imatinib has also been shown to inhibit other tyrosine kinases, including c-Kit and PDGFR, making it effective in treating gastrointestinal stromal tumors (GISTs) and other cancers.

**Why Each Wrong Option is Incorrect**
**Option A:** Imatinib is not primarily used in the treatment of breast cancer, which is often treated with hormone therapy, chemotherapy, or targeted agents such as trastuzumab.
**Option B:** Imatinib is not a chemotherapeutic agent that works by intercalating DNA, like doxorubicin or etoposide.
**Option C:** Imatinib is not a monoclonal antibody that targets specific antigens on cancer cells, like rituximab or trastuzumab.

**Clinical Pearl / High-Yield Fact**
Imatinib is a prime example of a targeted therapy that has revolutionized the treatment of CML and GISTs, and its development has led to a greater understanding of the molecular mechanisms underlying these diseases.

**Correct Answer: C. Chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).**